These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30921591)

  • 1. A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs.
    Hiebert L; Hecht R; Soe-Lin S; Mohamed R; Shabaruddin FH; Syed Mansor SM; Dahlui M; Azzeri A; McDonald SA
    Value Health Reg Issues; 2019 May; 18():112-120. PubMed ID: 30921591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation.
    Zhong H; Aaron A; Hiebert L; Serumondo J; Zhuo Y; Adee M; Rwibasira GN; Ward JW; Chhatwal J
    Value Health; 2024 Jul; 27(7):918-925. PubMed ID: 38492923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
    Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
    Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040.
    McDonald SA; Azzeri A; Shabaruddin FH; Dahlui M; Tan SS; Kamarulzaman A; Mohamed R
    Appl Health Econ Health Policy; 2018 Dec; 16(6):847-857. PubMed ID: 30145775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
    Dore GJ; Hajarizadeh B
    Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning.
    Trickey A; Hiebert L; Perfect C; Thomas C; El Kaim JL; Vickerman P; Schȕtte C; Hecht R
    Liver Int; 2020 Feb; 40(2):286-297. PubMed ID: 31454466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method.
    Hiebert L; Azzeri A; Dahlui M; Hecht R; Mohamed R; Hana Shabaruddin F; McDonald SA
    Subst Use Misuse; 2020; 55(6):871-877. PubMed ID: 31933411
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
    Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
    Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
    Jülicher P; Galli C
    J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.
    Chhatwal J; Chen Q; Wang X; Ayer T; Zhuo Y; Janjua NZ; Kanwal F
    JAMA Netw Open; 2019 May; 2(5):e193613. PubMed ID: 31074817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
    Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
    Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    Wisløff T; White R; Dalgard O; Amundsen EJ; Meijerink H; Kløvstad H
    J Viral Hepat; 2018 Sep; 25(9):1066-1077. PubMed ID: 29624813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis.
    Lim AG; Walker JG; Mafirakureva N; Khalid GG; Qureshi H; Mahmood H; Trickey A; Fraser H; Aslam K; Falq G; Fortas C; Zahid H; Naveed A; Auat R; Saeed Q; Davies CF; Mukandavire C; Glass N; Maman D; Martin NK; Hickman M; May MT; Hamid S; Loarec A; Averhoff F; Vickerman P
    Lancet Glob Health; 2020 Mar; 8(3):e440-e450. PubMed ID: 32087176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.